FDA Rescinds Approval of Oncopeptides' Blood Cancer Treatment: Implications and What's Next

In a groundbreaking decision, the US Food and Drug Administration (FDA) has rescinded its approval of a blood cancer treatment developed by Oncopeptides, a Swedish biotech firm. The drug, known as Pepaxto (melphalan flufenamide), was previously indicated for the treatment of multiple myeloma, a type of blood cancer.